Serum hsa_circ_0000615 is a prognostic biomarker of sorafenib resistance in hepatocellular carcinoma.

Lunjun Zhang,Tao Xu, Yuanyuan Li,Qing Pang, Xiaolin Ding

Journal of clinical laboratory analysis（2022）

引用 0|浏览6

暂无评分

摘要

Our results highlight hsa_circ_0000615 as a promising driver of sorafenib resistance in HCC patients, highlighting it as a promising target for the treatment of this deadly cancer type.

查看译文

关键词

hepatocellular carcinoma,hsa_circ_0000615,sorafenib resistance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要